logo
  

Genesco Q4 Profit Down, Misses View; Sees FY25 Earnings Below Street; Stock Down In Pre-market

Genesco Inc. (GCO), a specialty retailer of branded footwear and accessories, reported Friday that its fourth-quarter net earnings fell to $27.19 million from last year's $38.95 million.

Net earnings per share were $2.47, down from $3.21 a year ago.

Earnings from continuing operations were $20.29 million, compared to $39.20 million last year. Earnings per share from continuing operations were $1.84, compared to $3.23 last year.

Adjusted earnings from continuing operations were $28.5 million or $2.59 per share, compared to $37.1 million or $3.06 per share a year ago.

Analysts on average expected the company to report earnings of $3.04 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

Net sales of $738.95 million this year increased 2 percent from last year's $725 million, benefited by the additional 14th week. Excluding the 14th week, sales decreased 2 percent.

The Street was looking for sales of $705.66 million for the quarter.

Total Genesco Comparable Sales fell 4 percent, compared to a 5 percent growth last year.

Looking ahead for fiscal 2025, the company expects adjusted earnings per share from continuing operations in the range of $0.60 to $1.00, while analysts estimate $2.53 per share. In fiscal 2024, adjusted earnings from continuing operations were $0.56 per share.

The company expects total sales to decrease 2 percent to 3 percent compared to fiscal 2024, or down 1 percent to 2 percent excluding the 53rd week in fiscal 2024.

In pre-market activity on the NYSE, the shares were losing around 18.11 percent to trade at $23.97.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT